Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Jun 25, 2026
Reporting period
Not applicable
Filed with the SEC
Jun 26, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0002114900-26-000009
Filed / recorded
Jun 26, 2026, 10:45 PM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Krystal Biotech, Inc.
Issuer CIK
1711279
Ticker
KRYS
Reporting person
John Charles Thomas
Relationship
Officer
Officer title
EVP, General Counsel
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Jun 25, 2026
Transaction code
M
Shares / units
1,000
Price per share
$179.25
Acquired / disposed
Acquired (A)
Shares owned after
1,000
Ownership form
Direct
Amendment
No
Footnotes from the filing
The acquisition and sale of shares of the Company's common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. All transactions contemplated by the plan have been completed, and the plan has terminated in accordance with its terms.